Akebia | Pioneering Hypoxia Inducible Factor (HIF) Therapies

For information about Keryx programs for patients & families, please click here

For information about Keryx programs for medical professionals, please click here

So What is HIF?

HIF helps the body to adapt to conditions of low oxygen, similar to what is experienced at moderate altitude. Learn more about the potential therapeutic value of HIF.

Learn About our Approved Medicine

Our Pipeline

We’re Pursuing indications in kidney disease and other serious conditions.

The Science of High Altitude

We’re Exploring the Link Between Hypoxia and Treatment of Serious Diseases.

Recent Press Releases View All »

Thursday, December 13, 2018Akebia Therapeutics and Keryx Biopharmaceuticals Complete Merger, Creating Fully Integrated Renal Company

Tuesday, December 11, 2018Akebia Therapeutics Shareholders Approve Merger with Keryx

Monday, December 3, 2018Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Community News View All »

Akebia 2018 Spring Conference Recap Monday, September 10, 2018 We care deeply about the work we do as we strive to make a positive difference for patients suffering from chronic kidney disease. There is always more to learn, and this spring’s conference season provided multiple opportunities to meet with and exchange thoughts and information with our colleagues and partners in the nephrology field.

JP Morgan Healthcare Conference, San Francisco, CA Friday, January 12, 2018 We’re happy to report a great week of meetings.

American Society of Nephrology, New Orleans, LA Wednesday, November 1, 2017 Akebia recently attended the American Society of Nephrology (ASN) in New Orleans.

Join Us View All »

Manager, Quality Assurance GMP

VP, Biostatistics and Programming

Senior Medical Director, Clinical Development

Principal Scientist, DMPK

VP, Investor Relations and Corporate Communications

Scientist II, Analytical Research and Development